acarbose has been researched along with Diabetes Mellitus, Type 2 in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashraf, M; Bajda, M; Hussain, S; Khan, IU; Mustafa, G; Mutahir, S; Rehman, TU; Riaz, S; Shaukat, A; Yar, M | 1 |
| Al-Rashida, M; Ashraf, M; Asif, N; Chaudhry, F; Huma, R; Khan, MA; Munawar, MA; Naureen, S; Shaukat, A | 1 |
| Chigurupati, S; Imran, S; Irshad, M; Ismail, NH; Khan, KM; Nawaz, F; Rahim, F; Selvaraj, M; Taha, M | 1 |
| Ananthakrishnan, R; Jayamurthy, P; Krishnan, SL; Madhukrishnan, M; Manojkumar, TK; Neethu, S; Prabha, B; Radhakrishnan, KV; Rameshkumar, KB; Sherin, DR | 1 |
| Adib, M; Bijanzadeh, HR; Faramarzi, MA; Imanparast, S; Jahani, M; Larijani, B; Mahdavi, M; Mahernia, S; Mohammadi-Khanaposhtani, M; Peytam, F; Rahmanian-Jazi, M | 1 |
| Agarwal, R; Luthra, T; Naga Lalitha, K; Sen, S; Uma, A | 1 |
| Athrey, G; Jayaprakasha, GK; Patil, BS; Perera, WH; Perez, JL; Shivanagoudra, SR; Sun, Y; Wu, CS | 1 |
| Athipornchai, A; Chaidam, S; Saeeng, R; Saehlim, N; Sirion, U | 1 |
| Babkov, DA; Bezsonova, EN; Dubar, M; Klochkov, VG; Lozinskaya, NA; Melekhina, DD; Spasov, AA; Temnov, VV; Zaryanova, EV | 1 |
| Bnouham, M; Cherfi, M; Daoudi, NE; Harit, T; Malek, F; Oulous, A | 1 |
| Washburn, WN | 1 |
| Brindis, F; Bye, R; González-Andrade, M; Mata, R; Rodríguez, R | 1 |
| Adachi, I; Imahori, T; Kato, A; Murakami, K; Nakagawa, S; Natori, Y; Takahata, H; Yoshimura, Y | 1 |
| Dhumaskar, KL; Ghadi, SC; Meena, SN; Tilve, SG | 1 |
| Ahmed, M; Alam, U; Ashraf, M; Bajda, M; Khan, AF; Khan, IU; Shahzad, SA; Shahzadi, L; Yar, M | 1 |
1 review(s) available for acarbose and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
14 other study(ies) available for acarbose and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast α-glucosidase, acetylcholinesterase and butyrylcholinesterase.
Topics: Acetylcholinesterase; alpha-Glucosidases; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Molecular Docking Simulation; Molecular Structure; Pyridines; Saccharomyces cerevisiae; Structure-Activity Relationship; Sulfonamides | 2015 |
In search of new α-glucosidase inhibitors: Imidazolylpyrazole derivatives.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Molecular Docking Simulation; Pyrazoles; Saccharomyces cerevisiae; Structure-Activity Relationship | 2017 |
Synthesis of piperazine sulfonamide analogs as diabetic-II inhibitors and their molecular docking study.
Topics: alpha-Amylases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Molecular Docking Simulation; Molecular Structure; Piperazine; Piperazines; Structure-Activity Relationship; Sulfonamides | 2017 |
Antidiabetic potential of phytochemicals isolated from the stem bark of Myristica fatua Houtt. var. magnifica (Bedd.) Sinclair.
Topics: alpha-Glucosidases; Binding Sites; Cell Line; Cell Survival; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Molecular Dynamics Simulation; Muscle Cells; Myristicaceae; Phytochemicals; Plant Bark; Plant Extracts; Plant Stems; Protein Structure, Tertiary; Resorcinols | 2018 |
New 6-amino-pyrido[2,3-d]pyrimidine-2,4-diones as novel agents to treat type 2 diabetes: A simple and efficient synthesis, α-glucosidase inhibition, molecular modeling and kinetic study.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Kinetics; Models, Molecular; Molecular Structure; Pyridines; Pyrimidines; Structure-Activity Relationship | 2018 |
Design, synthesis and in vitro study of densely functionalized oxindoles as potent α-glucosidase inhibitors.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Drug Design; Glycoside Hydrolase Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Oxindoles; Structure-Activity Relationship; Yeasts | 2018 |
In vitro and in silico elucidation of antidiabetic and anti-inflammatory activities of bioactive compounds from Momordica charantia L.
Topics: Anti-Inflammatory Agents; Computer Simulation; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Inflammation; Momordica charantia | 2019 |
Synthesis and biological evaluation of 1,6-bis-triazole-2,3,4-tri-O-benzyl-α-d-glucopyranosides as a novel α-glucosidase inhibitor in the treatment of Type 2 diabetes.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Glucans; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Protein Binding; Protein Conformation | 2021 |
Towards multi-target antidiabetic agents: In vitro and in vivo evaluation of 3,5-disubstituted indolin-2-one derivatives as novel α-glucosidase inhibitors.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Indoles; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2022 |
New pyrazole-tetrazole hybrid compounds as potent α-amylase and non-enzymatic glycation inhibitors.
Topics: alpha-Amylases; Diabetes Mellitus, Type 2; Humans; Pyrazoles; Pyridines; Tetrazoles | 2022 |
(Z)-3-butylidenephthalide from Ligusticum porteri , an α-glucosidase inhibitor.
Topics: Acarbose; Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Insulin; Insulin Secretion; Ligusticum; Medicine, Traditional; Mexico; Mice; Phthalic Anhydrides; Stereoisomerism; Streptozocin | 2011 |
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of α-glucosidase inhibitors.
Topics: alpha-Glucosidases; Animals; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Furanoses; Rats | 2011 |
Graphite catalyzed solvent free synthesis of dihydropyrimidin-2(1H)-ones/thiones and their antidiabetic activity.
Topics: alpha-Amylases; Catalysis; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Enzyme Inhibitors; Graphite; Humans; Hypoglycemic Agents; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Thiones | 2014 |
Novel synthesis of dihydropyrimidines for α-glucosidase inhibition to treat type 2 diabetes: in vitro biological evaluation and in silico docking.
Topics: alpha-Glucosidases; Amino Acid Sequence; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glycoside Hydrolase Inhibitors; Molecular Docking Simulation; Molecular Sequence Data; Molecular Structure; Pyrimidines; Saccharomyces cerevisiae; Sequence Alignment; Structure-Activity Relationship | 2014 |